Our portfolio companies

Portfolio Our portfolio companies

NeRRe Therapeutics

NeRRe Therapeutics

Optimizing a unique neurokinin antagonist pipeline

NeRRe Therapeutics is a clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity resulting from neurokinin dysfunction. The focus of the company is to generate Phase 2 data on orvepitant, its lead oral NK-1 antagonist candidate as a potential novel treatment for a common, chronic respiratory condition; and to advance NT-814, a dual NK-1,3 antagonist, into Phase 2 trials as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

  • Industry Biotech